263 related articles for article (PubMed ID: 31368671)
1. Prognostic significance of molecular characteristics of cerebrospinal fluid for non-small cell lung cancer patients with leptomeningeal metastasis.
Li N; Liu Y; Duan J; Yang B; Bai H; Sun R; Yu L; Wang J
Thorac Cancer; 2019 Aug; 10(8):1673-1682. PubMed ID: 31368671
[TBL] [Abstract][Full Text] [Related]
2. Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy.
Xu Y; Hu M; Zhang M; Zhong W; Yin X; Sun Y; Chen M; Zhao J; Si X; Wang H; Zhang X; Zhang L; Li J; Guan H; Yang Z; Wang M
Lung Cancer; 2018 Nov; 125():142-149. PubMed ID: 30429013
[TBL] [Abstract][Full Text] [Related]
3. Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.
Wu YL; Zhao Q; Deng L; Zhang Y; Zhou XJ; Li YY; Yu M; Zhou L; Zou BW; Lu Y; Liu YM
Lung Cancer; 2019 Jan; 127():1-5. PubMed ID: 30642536
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis.
Wu H; Zhang Q; Zhai W; Chen Y; Yang Y; Xie M; Huang Z; Xu Y; Li H; Gong L; Yu S; Fan Y; Chen K
Lung Cancer; 2024 Feb; 188():107475. PubMed ID: 38266613
[TBL] [Abstract][Full Text] [Related]
5. The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer-a retrospective study from one single cancer institute.
Yan W; Jing W; An N; Tian Y; Guo D; Kong L; Zhu H; Yu J
Cancer Med; 2019 Jun; 8(6):2769-2776. PubMed ID: 30993909
[TBL] [Abstract][Full Text] [Related]
6. Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
Yang H; Wen L; Pan Y; Shan C; Hong W; Wang H; Zhou C; Cai L; Zhou C
BMC Cancer; 2022 May; 22(1):580. PubMed ID: 35614407
[TBL] [Abstract][Full Text] [Related]
7. Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis.
Yan W; Liu Y; Li J; Han A; Kong L; Yu J; Zhu H
Radiat Oncol; 2019 Sep; 14(1):168. PubMed ID: 31521171
[TBL] [Abstract][Full Text] [Related]
8. Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations.
Li YS; Jiang BY; Yang JJ; Tu HY; Zhou Q; Guo WB; Yan HH; Wu YL
J Thorac Oncol; 2016 Nov; 11(11):1962-1969. PubMed ID: 27539328
[TBL] [Abstract][Full Text] [Related]
9. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.
Lee SJ; Lee JI; Nam DH; Ahn YC; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2013 Feb; 8(2):185-91. PubMed ID: 23328548
[TBL] [Abstract][Full Text] [Related]
10. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.
Flippot R; Biondani P; Auclin E; Xiao D; Hendriks L; Le Rhun E; Leduc C; Beau-Faller M; Gervais R; Remon J; Adam J; Planchard D; Lavaud P; Naltet C; Caramella C; Le Pechoux C; Lacroix L; Gazzah A; Mezquita L; Besse B
J Thorac Oncol; 2019 Aug; 14(8):1400-1407. PubMed ID: 31108248
[TBL] [Abstract][Full Text] [Related]
11. Epidermal Growth Factor Receptor Mutation Detection in Cerebrospinal Fluid of Lung Adenocarcinoma Patients with Leptomeningeal Metastasis.
Huang R; Ge M; Zhou X; Ji X; Liao L; Liang X; Zhan Q
Cancer Biother Radiopharm; 2019 Mar; 34(2):128-133. PubMed ID: 30452286
[TBL] [Abstract][Full Text] [Related]
12. Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer.
Liu X; Li G; Zhang H; Chang Q; Fang M; Lu C; Tian P; Mei F
Clin Neurol Neurosurg; 2023 Feb; 225():107572. PubMed ID: 36610238
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.
Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS
Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628
[TBL] [Abstract][Full Text] [Related]
14. Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.
Miyawaki T; Kenmotsu H; Yabe M; Kodama H; Nishioka N; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Ono A; Deguchi S; Mitsuya K; Naito T; Murakami H; Mori K; Harada H; Hayashi N; Takahashi K; Takahashi T
Invest New Drugs; 2021 Dec; 39(6):1732-1741. PubMed ID: 34259953
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid circulating tumour DNA genotyping and survival analysis in lung adenocarcinoma with leptomeningeal metastases.
Bai K; Chen X; Qi X; Zhang Y; Zou Y; Li J; Yu L; Li Y; Jiang J; Yang Y; Liu Y; Feng S; Bu H
J Neurooncol; 2023 Oct; 165(1):149-160. PubMed ID: 37897649
[TBL] [Abstract][Full Text] [Related]
16. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of Clinicopathological Feature and Prognosis for
Leptomeningeal Metastasis in Non-small Cell Lung Cancer].
Zhu M; Ren Y; Liu Y; Ban C; Gu H; Wang Z; Zhang Y
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):533-8. PubMed ID: 27561804
[TBL] [Abstract][Full Text] [Related]
18. Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis.
Chiang CL; Lee CC; Huang HC; Wu CH; Yeh YC; Shen CI; Luo YH; Shiao TH; Chang HJ; Huang YT; Chen YM; Chou TY; Chiu CH
Target Oncol; 2021 Mar; 16(2):207-214. PubMed ID: 33566300
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Real-World Study of Prognostic Factors Associated With EGFR Mutated Lung Cancer With Leptomeningeal Metastasis.
Wu Y; Zhao Y; Wu Y; Chen H; Ma S; Wang Q
Clin Lung Cancer; 2024 Jun; 25(4):347-353.e1. PubMed ID: 38418264
[TBL] [Abstract][Full Text] [Related]
20. Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial.
Lu ZQ; Cai J; Wang X; Wei JP; Zeng ZM; Huang L; Liu AW
Thorac Cancer; 2021 Jan; 12(2):172-180. PubMed ID: 33205587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
